Circulating natural killer cells and their association with breast cancer and its clinico-pathological characteristics

Homian N'da Marcelin; Romuald S Dasse; Richard O Yeboah; Agnès D Tariam; Arsène G Z Kagambega; Akandji M Oseni; Y K K Kouassi; Michel A Bilé; Moctar Toure; Monica Thakar; Innocent Adoubi; Darya Kizub

doi:10.3332/ecancer.2023.1567

Circulating natural killer cells and their association with breast cancer and its clinico-pathological characteristics

Ecancermedicalscience. 2023 Jul 3:17:1567. doi: 10.3332/ecancer.2023.1567. eCollection 2023.

Affiliations

¹ Department of Oncology, Centre Hospitalier Universitaire de Treichville, 7XVV+5P4, Abidjan, Côte d'Ivoire.
² Department of Immunology, Centre Hospitalier Universitaire de Cocody, BP V 3, Abidjan, Côte d'Ivoire.
³ The Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
⁴ University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Abstract

Purpose: Natural killer (NK) cells play a critical role in cancer immunosurveillance and hold promise as both therapies and prognostic markers in advanced disease. We explore factors that may influence NK cell concentration in the peripheral blood of women with breast cancer in Côte d'Ivoire compared to healthy controls and implications for future research in our context.

Methods: In this cross-sectional case-control study, blood samples were taken from 30 women diagnosed with breast cancer within 6 months of diagnosis and fifteen healthy women at University Teaching Hospital [Centre Hospitalier Universitaire (CHU)] Treichville in Abidjan, Côte d'Ivoire, from March to September 2018. The blood draw could take place at any time following diagnosis and through treatment. Demographic and clinical data were collected. NK cells were isolated, stained, analysed and counted using the flow cytometer at the Department of Immunology at CHU of Cocody. All p-values were two-sided.

Results: Mean age among 30 women with breast cancer was 49 years old compared to 45 years old for 15 controls (p = 0.41). Among 30 women with breast cancer, 4 (13.3%) had Stage 2 disease, 14 (46.7 %) at Stage 3, and 12 (40%) at Stage 4. Fourteen (46.7%) had breast cancer that was hormone receptor-positive (HR+) HER2-negative, 10 (33.3%) had triple-negative cancer, three (10.0%) had HR+HER2+ disease, and three (10.0%) HR-HER2+ cancer. NK cell concentration was not associated with cancer diagnosis, age, cancer stage, subtype, or type of treatment patients received (p > 0.05).

Conclusion: Although we did not find an association between NK cell concentration, cancer characteristics or treatment, our results be limited by the small sample size and timing of blood draw. Our next steps include a larger study to explore circulating NK cells prior to any treatment and NK cell infiltration within breast cancer tumour and correlating this with response to treatment and prognosis.

Keywords: breast cancer; natural killer (NK) cells; treatment.